CTOs on the Move

NeuBase Therapeutics

www.neubasetherapeutics.com

 
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Anthony Rossomando
 Chief Technology Officer Profile

Similar Companies

Onyx Pharmaceuticals

At Onyx Pharmaceuticals, an Amgen subsidiary, our imperative is to build a leading cancer therapeutics company like no other, working toward a unified goal that drives us forward…to deliver breakthrough cancer treatments to patients with the urgency they deserve.   By working in collaboration with patient advocacy groups, healthcare providers and business partners, we push the boundaries of science and cancer therapeuticdevelopment.

Javelin Pharmaceuticals

Javelin Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enliven Therapeutics

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to help patients with cancer live longer and better.

WEX Pharmaceuticals

WEX Pharmaceuticals Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Associates of Cape Cod

Associates of Cape Cod is a East Falmouth, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.